Sino Biopharmaceutical Wins China First-Line Approval for Oral HER2 Lung Cancer Drug

Sino Biopharmaceutical ( (HK:1177) ) has issued an announcement.

Sino Biopharmaceutical announced that zongertinib, an oral HER2 tyrosine kinase inhibitor it co-promotes with Boehringer Ingelheim, has received conditional approval from China’s National Medical Products Administration as a first-line monotherapy for adults with unresectable locally advanced or metastatic HER2-mutant non-small cell lung cancer. The drug, described as the world’s first approved oral HER2 tyrosine kinase inhibitor, addresses a significant unmet need in a patient group with poor prognosis and limited benefit from existing chemotherapy, immunotherapy and antibody-drug conjugates, and its strong Phase 1b data, including high response rates and activity in brain metastases, could enhance Sino Biopharmaceutical’s oncology portfolio and strengthen its strategic collaboration with Boehringer Ingelheim in the competitive Chinese cancer market.

The approval is supported by results from the Beamion-LUNG 1 trial, where treatment-naive patients showed a 76% confirmed objective response rate and meaningful durability of response and progression-free survival, with additional evidence of intracranial efficacy in patients with active brain metastases. Ongoing BEAMION trials, including a Phase III study comparing zongertinib with standard of care in HER2-mutant non-squamous NSCLC, may further define the drug’s role in treatment guidelines and reinforce the partners’ ambitions to bring more innovative oncology therapies to Chinese patients, potentially improving outcomes while offering the convenience of oral administration.

The most recent analyst rating on (HK:1177) stock is a Buy with a HK$6.50 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.

More about Sino Biopharmaceutical

Sino Biopharmaceutical Limited is a China-focused pharmaceutical group engaged in the research, development, manufacturing and commercialization of innovative therapies, with a growing emphasis on oncology. The company co-promotes certain advanced cancer drugs in mainland China through strategic partnerships, aiming to expand its presence in precision medicine and targeted treatments.

Average Trading Volume: 75,123,192

Technical Sentiment Signal: Buy

Current Market Cap: HK$92.38B

Find detailed analytics on 1177 stock on TipRanks’ Stock Analysis page.